Leukine GM-CSF data

Preliminary results of a Phase III trial in 118 evaluable patients showed a significantly shorter time to neutrophil recovery after chemotherapy, without the bone marrow transplant that is typically required. The rate of complete remission was 61 percent for the patients treated with GM-CSF and 46 percent for the control group. The data were scheduled for presentation today at ASH.

Patients receiving GM-CSF took fewer days to achieve a neutrophil count of more than 500/µl compared to those treated with a placebo (p < 0.01); and fewer days to reach more than 1,000 neutrophils/µl (p < 0.001). ...